Ronald C Petersen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6309328/publications.pdf

Version: 2024-02-01

520 papers	59,279 citations	1994 101 h-index	1385 222 g-index
554 all docs	554 docs citations	554 times ranked	41464 citing authors

#	Article	IF	Citations
1	Association between CSF biomarkers of Alzheimer's disease and neuropsychiatric symptoms: Mayo Clinic Study of Aging. Alzheimer's and Dementia, 2023, 19, 4498-4506.	0.8	17
2	Association of Indication for Hospitalization With Subsequent Amyloid Positron Emission Tomography and Magnetic Resonance Imaging Biomarkers. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2023, 78, 304-313.	3.6	0
3	Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline. Alzheimer's and Dementia, 2022, 18, 602-611.	0.8	20
4	Detection of Alzheimer's disease amyloid beta 1â€42, pâ€tau, and tâ€tau assays. Alzheimer's and Dementia, 2022, 18, 635-644.	0.8	28
5	Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities. Alzheimer's and Dementia, 2022, 18, 1128-1140.	0.8	88
6	Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease. Alzheimer's and Dementia, 2022, 18, 824-857.	0.8	56
7	Regional Brain Stiffness Analysis of Dementia with Lewy Bodies. Journal of Magnetic Resonance Imaging, 2022, 55, 1907-1909.	3.4	0
8	Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases. Brain, 2022, 145, 27-44.	7.6	38
9	Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum. Alzheimer's and Dementia, 2022, 18, 1370-1382.	0.8	17
10	The temporal onset of the core features in dementia with Lewy bodies. Alzheimer's and Dementia, 2022, 18, 591-601.	0.8	19
11	Clinical Deep Phenotyping of ABCA7 Mutation Carriers. Neurology: Genetics, 2022, 8, e655.	1.9	4
12	Long-term associations between amyloid positron emission tomography, sex, apolipoprotein E and incident dementia and mortality among individuals without dementia: hazard ratios and absolute risk. Brain Communications, 2022, 4, fcac017.	3.3	12
13	1H MR spectroscopy biomarkers of neuronal and synaptic function are associated with tau deposition in cognitively unimpaired older adults. Neurobiology of Aging, 2022, 112, 16-26.	3.1	9
14	TDP-43-associated atrophy in brains with and without frontotemporal lobar degeneration. NeuroImage: Clinical, 2022, 34, 102954.	2.7	3
15	Longitudinal atrophy in prodromal dementia with Lewy bodies points to cholinergic degeneration. Brain Communications, 2022, 4, fcac013.	3.3	15
16	White matter damage due to vascular, tau, and TDP-43 pathologies and its relevance to cognition. Acta Neuropathologica Communications, 2022, 10, 16.	5.2	14
17	Where Do We Go from Here?. journal of prevention of Alzheimer's disease, The, 2022, 9, 188-189.	2.7	1
18	Are plasma markers for Alzheimerâ€™s disease ready for clinical use?. Nature Aging, 2022, 2, 94-96.	11.6	1

#	Article	IF	Citations
19	TDP-43 represses cryptic exon inclusion in the FTDâ€“ALS gene UNC13A. Nature, 2022, 603, 124-130.	27.8	193
20	Phenotypic subtypes of progressive dysexecutive syndrome due to Alzheimerâ€™s disease: a series of clinical cases. Journal of Neurology, 2022, 269, 4110-4128.	3.6	7
21	Screening and enrollment of underrepresented ethnocultural and educational populations in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimer's and Dementia, 2022, 18, 2603-2613.	0.8	10
22	Clinicopathologic Factors Associated With Reversion to Normal Cognition in Patients With Mild Cognitive Impairment. Neurology, 2022, 98, .	1.1	7
23	Reply to A Letter Concerning â€œAducanumab: What About the Patient?â€• Annals of Neurology, 2022, 91, 733-734.	5.3	0
24	Detecting Alzheimer Disease Clinically. Neurology, 2022, 98, 607-608.	1.1	1
25	Longitudinal Tau Positron Emission Tomography in Dementia with Lewy Bodies. Movement Disorders, 2022, 37, 1256-1264.	3.9	11
26	Poly (ADP-Ribose) and Î±â€“synuclein extracellular vesicles in patients with Parkinson disease: A possible biomarker of disease severity. PLoS ONE, 2022, 17, e0264446.	2.5	6
27	A longitudinal investigation of AÎ², anxiety, depression, and mild cognitive impairment. Alzheimer's and Dementia, 2022, 18, 1824-1831.	0.8	14
28	Shared brain transcriptomic signature in TDP-43 type A FTLD patients with or without GRN mutations. Brain, 2022, 145, 2472-2485.	7.6	6
29	Tau polygenic risk scoring: a cost-effective aid for prognostic counseling in Alzheimerâ€™s disease. Acta Neuropathologica, 2022, 143, 571-583.	7.7	3
30	Deep learning-based brain age prediction in normal aging and dementia. Nature Aging, 2022, 2, 412-424.	11.6	52
31	Frequency and distribution of TAR DNA-binding protein 43 (TDP-43) pathology increase linearly with age in a large cohort of older adults with and without dementia. Acta Neuropathologica, 2022, 144, 159-160.	7.7	14
32	Artificial Intelligenceâ€“Enabled Electrocardiogram for Atrial Fibrillation Identifies Cognitive Decline Risk and Cerebral Infarcts. Mayo Clinic Proceedings, 2022, 97, 871-880.	3.0	6
33	Association Between Plasma Biomarkers of Amyloid, Tau, and Neurodegeneration with Cerebral Microbleeds. Journal of Alzheimer's Disease, 2022, 87, 1537-1547.	2.6	4
34	Autosomal dominant and sporadic late onset Alzheimer's disease share a commonin vivopathophysiology. Brain, 2022, 145, 3594-3607.	7.6	20
35	Performance of plasma phosphorylated tau 181 and 217 in the community. Nature Medicine, 2022, 28, 1398-1405.	30.7	114
36	Alzheimer's disease cerebrospinal fluid biomarkers differentiate patients with Creutzfeldtâ€“Jakob disease and autoimmune encephalitis. European Journal of Neurology, 2022, 29, 2905-2912.	3.3	4

#	Article	IF	Citations
37	Prediction of Incident Dementia Using Patient Temporal Health Status. Studies in Health Technology and Informatics, 2022, , .	0.3	1
38	Polygenic Scores of Alzheimerâ€™s Disease Risk Genes Add Only Modestly to APOE in Explaining Variation in Amyloid PET Burden. Journal of Alzheimer's Disease, 2022, 88, 1615-1625.	2.6	2
39	Brain Regional Glucose Metabolism, Neuropsychiatric Symptoms, and the Risk of Incident Mild Cognitive Impairment: The Mayo Clinic Study of Aging. American Journal of Geriatric Psychiatry, 2021, 29, 179-191.	1.2	25
40	Association of Hospitalization with Longâ€Term Cognitive Trajectories in Older Adults. Journal of the American Geriatrics Society, 2021, 69, 660-668.	2.6	18
41	Association between surgery with anesthesia and cognitive decline in older adults: Analysis using shared parameter models for informative dropout. Journal of Clinical and Translational Science, 2021, 5, e27.	0.6	3
42	Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers. NeuroImage, 2021, 224, 117433.	4.2	63
43	Association of Initial Î²-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment. JAMA Neurology, 2021, 78, 217.	9.0	27
44	Brain MRI after critical care admission: A longitudinal imaging study. Journal of Critical Care, 2021, 62, 117-123.	2.2	7
45	Physical Activity and Trajectory of Cognitive Change in Older Persons: Mayo Clinic Study of Aging. Journal of Alzheimer's Disease, 2021, 79, 377-388.	2.6	12
46	The value of multimodal imaging with 123I-FP-CIT SPECT in differential diagnosis of dementia with Lewy bodies and Alzheimer's disease dementia. Neurobiology of Aging, 2021, 99, 11-18.	3.1	11
47	Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel. JAMA Neurology, 2021, 78, 102.	9.0	144
48	Association of Cortical and Subcortical Î²-Amyloid With Standardized Measures of Depressive and Anxiety Symptoms in Adults Without Dementia. Journal of Neuropsychiatry and Clinical Neurosciences, 2021, 33, 64-71.	1.8	9
49	Mayo Normative Studies: Regression-Based Normative Data for the Auditory Verbal Learning Test for Ages 30â€“91 Years and the Importance of Adjusting for Sex. Journal of the International Neuropsychological Society, 2021, 27, 211-226.	1.8	33
50	Î²-Amyloid PET and ¹²³ I-FP-CIT SPECT in Mild Cognitive Impairment at Risk for Lewy Body Dementia. Neurology, 2021, 96, .	1.1	13
51	FDG PET metabolic signatures distinguishing prodromal DLB and prodromal AD. NeuroImage: Clinical, 2021, 31, 102754.	2.7	27
52	Detection of Î²-amyloid positivity in Alzheimerâ€™s Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers. Brain Communications, 2021, 3, fcab008.	3.3	51
53	Gait Speed and Instrumental Activities of Daily Living in Older Adults After Hospitalization: A Longitudinal Population-Based Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, e272-e280.	3.6	1
54	Coping with brain amyloid: genetic heterogeneity and cognitive resilience to Alzheimerâ€™s pathophysiology. Acta Neuropathologica Communications, 2021, 9, 48.	5.2	18

#	Article	IF	Citations
55	National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome. Neurology, 2021, 96, 848-863.	1.1	149
56	Comparison of CSF neurofilament light chain, neurogranin, and tau to MRI markers. Alzheimer's and Dementia, 2021, 17, 801-812.	0.8	18
57	TAR DNA-Binding Protein 43 Is Associated with Rate of Memory, Functional and Global Cognitive Decline in the Decade Prior to Death. Journal of Alzheimer's Disease, 2021, 80, 683-693.	2.6	7
58	Neuropsychiatric symptoms and the outcome of cognitive trajectories in older adults free of dementia: The Mayo Clinic Study of Aging. International Journal of Geriatric Psychiatry, 2021, 36, 1362-1369.	2.7	16
59	Diagnostic accuracy of the Cogstate Brief Battery for prevalent MCI and prodromal AD (MCI) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf	0.8	16
60	White matter abnormalities are key components of cerebrovascular disease impacting cognitive decline. Brain Communications, 2021, 3, fcab076.	3.3	13
61	<scp>NIAâ€AA</scp> Alzheimer's Disease Framework: Clinical Characterization of Stages. Annals of Neurology, 2021, 89, 1145-1156.	5.3	31
62	Diffusion models reveal white matter microstructural changes with ageing, pathology and cognition. Brain Communications, 2021, 3, fcab106.	3.3	38
63	Long-read targeted sequencing uncovers clinicopathological associations for C9orf72-linked diseases. Brain, 2021, 144, 1082-1088.	7.6	17
64	Transcriptomic analysis to identify genes associated with selective hippocampal vulnerability in Alzheimerâ€™s disease. Nature Communications, 2021, 12, 2311.	12.8	44
65	Cerebral Amyloid Angiopathy Burden and Cerebral Microbleeds: Pathological Evidence for Distinct Phenotypes. Journal of Alzheimer's Disease, 2021, 81, 113-122.	2.6	8
66	Alzheimer disease. Nature Reviews Disease Primers, 2021, 7, 33.	30.5	784
67	MRI quantitative susceptibility mapping of the substantia nigra as an early biomarker for Lewy body disease. Journal of Neuroimaging, 2021, 31, 1020-1027.	2.0	13
68	Changing the face of neuroimaging research: Comparing a new MRI de-facing technique with popular alternatives. NeuroImage, 2021, 231, 117845.	4.2	38
69	CSF dynamics as a predictor of cognitive progression. NeuroImage, 2021, 232, 117899.	4.2	3
70	Lipidomic Network of Mild Cognitive Impairment from the Mayo Clinic Study of Aging. Journal of Alzheimer's Disease, 2021, 81, 533-543.	2.6	3
71	Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks. Brain, 2021, 144, 3212-3225.	7.6	26
72	Cerebral Microbleeds. Stroke, 2021, 52, 2347-2355.	2.0	9

#	Article	IF	Citations
73	Lack of physical activity, neuropsychiatric symptoms and the risk of incident mild cognitive impairment in older community-dwelling individuals. German Journal of Exercise and Sport Research, 2021, 51, 487-494.	1.2	5
74	MCI Criteria in ADNI. Neurology, 2021, 97, 597-599.	1.1	5
75	Aducanumab: What about the Patient?. Annals of Neurology, 2021, 90, 334-335.	5.3	10
76	Posterior cortical atrophy phenotypic heterogeneity revealed by decoding 18F-FDG-PET. Brain Communications, 2021, 3, fcab182.	3.3	12
77	Cerebral Amyloid Angiopathy Pathology and Its Association With Amyloid-Î² PET Signal. Neurology, 2021, 97, e1799-e1808.	1.1	10
78	Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation. NeuroImage, 2021, 238, 118259.	4.2	24
79	Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. JAMA Neurology, 2021, 78, 1108.	9.0	114
80	Pilot Evaluation of the Unsupervised, At-Home Cogstate Brief Battery in ADNI-2. Journal of Alzheimer's Disease, 2021, 83, 915-925.	2.6	8
81	A Comparison of Cross-Sectional and Longitudinal Methods of Defining Objective Subtle Cognitive Decline in Preclinical Alzheimerâ€™s Disease Based on Cogstate One Card Learning Accuracy Performance. Journal of Alzheimer's Disease, 2021, 83, 861-877.	2.6	7
82	Medical and nursing home costs: From cognitively unimpaired through dementia. Alzheimer's and Dementia, 2021, , .	0.8	1
83	APOE3 -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia. Science Translational Medicine, 2021, 13, eabc9375.	12.4	37
84	Sex Difference in the Relation Between Marital Status and Dementia Risk in Two Population-Based Cohorts. Journal of Alzheimer's Disease, 2021, 83, 1269-1279.	2.6	8
85	Cerebrovascular disease, neurodegeneration, and clinical phenotype in dementia with Lewy bodies. Neurobiology of Aging, 2021, 105, 252-261.	3.1	18
86	Relationships between Î²-amyloid and tau in an elderly population: An accelerated failure time model. NeuroImage, 2021, 242, 118440.	4.2	15
87	Longitudinal deterioration of white-matter integrity: heterogeneity in the ageing population. Brain Communications, 2021, 3, fcaa238.	3.3	11
88	Reply to â€œThinking beyond Aducanumab Controversyâ€. Annals of Neurology, 2021, 90, 1004-1004.	5.3	0
89	Cerebrospinal Fluid Dynamics and Discordant Amyloid Biomarkers. Neurobiology of Aging, 2021, 110, 27-36.	3.1	7
90	Connecting Cohorts to Diminish Alzheimerâ€™s Disease (CONCORD-AD): A Report of an International Research Collaboration Network. Journal of Alzheimer's Disease, 2021, , 1-15.	2.6	1

#	Article	IF	Citations
91	Longitudinally Increasing Elevated Asymmetric Flortaucipir Binding in a Cognitively Unimpaired Amyloid-Negative Older Individual. Journal of Alzheimer's Disease, 2021, , 1-6.	2.6	1
92	Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes. Alzheimer's Research and Therapy, 2021, 13, 199.	6.2	32
93	CSF and blood plasma mass spectrometry measures of AÎ², tau, and NfL species and longitudinal relationship to preclinical and clinical staging of amyloid and tau aggregation and clinical stage of Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.8	1
94	The Overlap Index: A new means for early detection of serial tau PET signal change. Alzheimer's and Dementia, 2021, 17, .	0.8	0
95	Early Alert of Elderly Cognitive Impairment using Temporal Streaming Clustering. , 2021, 2021, 905-912.		3
96	The screening and enrollment of underrepresented ethnoracial and educational populations in the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia, 2021, 17, .	0.8	1
97	Diffusion models reveal white matter microstructural changes with aging, pathology, and cognition. Alzheimer's and Dementia, 2021, 17, .	0.8	0
98	Successful cognitive aging definitions and associated demographic, biomarker profiles and lifestyles in the 80+ MCSA population. Alzheimer's and Dementia, 2021, 17, .	0.8	0
99	Cardiorespiratory Fitness and Brain Volumes. Mayo Clinic Proceedings, 2020, 95, 6-8.	3.0	5
100	Linear vs volume measures of ventricle size. Neurology, 2020, 94, e549-e556.	1.1	19
101	Cerebral microbleed incidence, relationship to amyloid burden. Neurology, 2020, 94, e190-e199.	1.1	31
102	Brain imaging measurements of fibrillar amyloidâ€Î² burden, paired helical filament tau burden, and atrophy in cognitively unimpaired persons with two, one, and no copies of the APOE Îµ4 allele. Alzheimer's and Dementia, 2020, 16, 598-609.	0.8	23
103	Incidence of frontotemporal disorders in Olmsted County: A populationâ€based study. Alzheimer's and Dementia, 2020, 16, 482-490.	0.8	11
104	Tauâ€positron emission tomography correlates with neuropathology findings. Alzheimer's and Dementia, 2020, 16, 561-571.	0.8	113
105	Longitudinal flortaucipir ([18F]AV-1451) PET imaging in primary progressive apraxia of speech. Cortex, 2020, 124, 33-43.	2.4	5
106	Î²-Amyloid PET and neuropathology in dementia with Lewy bodies. Neurology, 2020, 94, e282-e291.	1.1	65
107	Î²-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies. Neurology, 2020, 95, e3257-e3268.	1.1	62
108	Predicting future rates of tau accumulation on PET. Brain, 2020, 143, 3136-3150.	7.6	74

#	Article	IF	Citations
109	Reduced fractional anisotropy of the genu of the corpus callosum as a cerebrovascular disease marker and predictor of longitudinal cognition in MCI. Neurobiology of Aging, 2020, 96, 176-183.	3.1	27
110	Variants inPPP2R2BandIGF2BP3are associated with higher tau deposition. Brain Communications, 2020, 2, fcaa159.	3.3	12
111	Artificial Intelligenceâ€“Electrocardiography to Predict Incident Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e009355.	4.8	68
112	Genomeâ€wide transcriptome analysis identifies novel dysregulated genes implicated in Alzheimer's pathology. Alzheimer's and Dementia, 2020, 16, 1213-1223.	0.8	23
113	Association of ABI3 and PLCG2 missense variants with disease risk and neuropathology in Lewy body disease and progressive supranuclear palsy. Acta Neuropathologica Communications, 2020, 8, 172.	5.2	8
114	Association Between Neuropsychiatric Symptoms and Functional Change in Older Non-Demented Adults: Mayo Clinic Study of Aging. Journal of Alzheimer's Disease, 2020, 78, 911-917.	2.6	3
115	Associations Between Plasma Ceramides and Cerebral Microbleeds or Lacunes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 2785-2793.	2.4	7
116	Tau and apolipoprotein E modulate cerebrovascular tight junction integrity independent of cerebral amyloid angiopathy in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, 1372-1383.	0.8	34
117	NIAâ€AA AD framework stage 2: Performance in the community. Alzheimer's and Dementia, 2020, 16, e040262.	0.8	0
118	MAPT subhaplotypes in corticobasal degeneration: assessing associations with disease risk, severity of tau pathology, and clinical features. Acta Neuropathologica Communications, 2020, 8, 218.	5.2	8
119	Protein contributions to brain atrophy acceleration in Alzheimerâ€™s disease and primary age-related tauopathy. Brain, 2020, 143, 3463-3476.	7.6	45
120	Cortical atrophy patterns of incident MCI subtypes in the Mayo Clinic Study of Aging. Alzheimer's and Dementia, 2020, 16, 1013-1022.	0.8	20
121	Prevalence and Heterogeneity of Cerebrovascular Disease Imaging Lesions. Mayo Clinic Proceedings, 2020, 95, 1195-1205.	3.0	30
122	Utility of FDG-PET in diagnosis of Alzheimer-related TDP-43 proteinopathy. Neurology, 2020, 95, e23-e34.	1.1	27
123	Longitudinal neuroimaging biomarkers differ across Alzheimerâ€™s disease phenotypes. Brain, 2020, 143, 2281-2294.	7.6	51
124	Diagnostic and Prognostic Accuracy of the Cogstate Brief Battery and Auditory Verbal Learning Test in Preclinical Alzheimerâ€™s Disease and Incident Mild Cognitive Impairment: Implications for Defining Subtle Objective Cognitive Impairment. Journal of Alzheimer's Disease, 2020, 76, 261-274.	2.6	25
125	Subtypes of dementia with Lewy bodies are associated with Î±-synuclein and tau distribution. Neurology, 2020, 95, e155-e165.	1.1	47
126	Exposure to surgery with general anaesthesia during adult life is not associated with increased brain amyloid deposition in older adults. British Journal of Anaesthesia, 2020, 124, 594-602.	3.4	14

#	Article	IF	Citations
127	Preoperative cognitive impairment associated with oversedation during recovery from anesthesia. Journal of Anesthesia, 2020, 34, 390-396.	1.7	2
128	Witnessed apneas are associated with elevated tau-PET levels in cognitively unimpaired elderly. Neurology, 2020, 94, e1793-e1802.	1.1	28
129	CSF biomarkers in Olmsted County. Neurology, 2020, 95, e256-e267.	1.1	14
130	Longitudinal flortaucipir ([18F]AV-1451) PET uptake in semantic dementia. Neurobiology of Aging, 2020, 92, 135-140.	3.1	3
131	18F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies. Brain Communications, 2020, 2, fcaa040.	3.3	17
132	A soluble truncated tau species related to cognitive dysfunction is elevated in the brain of cognitively impaired human individuals. Scientific Reports, 2020, 10, 3869.	3.3	26
133	Better stress coping associated with lower tau in amyloid-positive cognitively unimpaired older adults. Neurology, 2020, 94, e1571-e1579.	1.1	18
134	Medical Doctors and Dementia: A Longitudinal Study. Journal of the American Geriatrics Society, 2020, 68, 1250-1255.	2.6	0
135	Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis. Annals of Neurology, 2020, 87, 556-567.	5.3	17
136	Effect Modifiers of TDP-43-Associated Hippocampal Atrophy Rates in Patients with Alzheimerâ€™s Disease Neuropathological Changes. Journal of Alzheimer's Disease, 2020, 73, 1511-1523.	2.6	14
137	TDP-43 is associated with a reduced likelihood of rendering a clinical diagnosis of dementia with Lewy bodies in autopsy-confirmed cases of transitional/diffuse Lewy body disease. Journal of Neurology, 2020, 267, 1444-1453.	3.6	4
138	International drive to illuminate delirium: A developing public health blueprint for action. Alzheimer's and Dementia, 2020, 16, 711-725.	0.8	31
139	MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous. Annals of Clinical and Translational Neurology, 2020, 7, 707-721.	3.7	17
140	Brain amyloid, cortical thickness, and changes in activities of daily living. Annals of Clinical and Translational Neurology, 2020, 7, 474-485.	3.7	3
141	Association between transactive response DNA-binding protein ofÂ43 kDa type and cognitive resilience to Alzheimerâ€™s disease: aÂcase-control study. Neurobiology of Aging, 2020, 92, 92-97.	3.1	13
142	The quest for dementia prevention does not include an aspirin a day. Neurology, 2020, 95, 105-106.	1.1	2
143	Pickâ€™s disease: clinicopathologic characterization of 21 cases. Journal of Neurology, 2020, 267, 2697-2704.	3.6	17
144	Associations between cerebrospinal fluid total phosphatidylcholines, neurodegeneration, cognitive decline, and risk of mild cognitive impairment in the Mayo Clinic Study of Aging. Neurobiology of Aging, 2020, 93, 52-54.	3.1	1

#	Article	IF	Citations
145	Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia. Journal of Clinical Investigation, 2020, 130, 6080-6092.	8.2	117
146	Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies. Acta Neuropathologica Communications, 2020, 8, 5.	5.2	27
147	Longitudinal anatomic, functional, and molecular characterization of Pick disease phenotypes. Neurology, 2020, 95, e3190-e3202.	1.1	13
148	The Association of Multimorbidity With Preclinical AD Stages and SNAP in Cognitively Unimpaired Persons. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2019, 74, 877-883.	3.6	16
149	Association of non-exercise physical activity in mid- and late-life with cognitive trajectories and the impact of APOE Îµ4 genotype status: the Mayo Clinic Study of Aging. European Journal of Ageing, 2019, 16, 491-502.	2.8	9
150	Informant-based hearing difficulties and the risk for mild cognitive impairment and dementia. Age and Ageing, 2019, 48, 888-894.	1.6	13
151	Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Agingâ€“Alzheimerâ€™s Association Research Framework. JAMA Neurology, 2019, 76, 1174.	9.0	182
152	Comparison of the Short Test of Mental Status and the Montreal Cognitive Assessment Across the Cognitive Spectrum. Mayo Clinic Proceedings, 2019, 94, 1516-1523.	3.0	35
153	Exposure to surgery under general anaesthesia and brain magnetic resonance imaging changes in older adults. British Journal of Anaesthesia, 2019, 123, 808-817.	3.4	13
154	Extensive transcriptomic study emphasizes importance of vesicular transport in C9orf72 expansion carriers. Acta Neuropathologica Communications, 2019, 7, 150.	5.2	40
155	Association of Apolipoprotein E É›4, Educational Level, and Sex With Tau Deposition and Tau-Mediated Metabolic Dysfunction in Older Adults. JAMA Network Open, 2019, 2, e1913909.	5.9	41
156	Amyloid, Vascular, and Resilience Pathways Associated with Cognitive Aging. Annals of Neurology, 2019, 86, 866-877.	5.3	40
157	Incidence of Convexal Subarachnoid Hemorrhage in the Elderly: The Mayo Clinic Study of Aging. Journal of Stroke and Cerebrovascular Diseases, 2019, 28, 104451.	1.6	1
158	Comparison of variables associated with cerebrospinal fluid neurofilament, totalâ€tau, and neurogranin. Alzheimer's and Dementia, 2019, 15, 1437-1447.	0.8	38
159	Population-Based Evaluation of Lumbar Puncture Opening Pressures. Frontiers in Neurology, 2019, 10, 899.	2.4	25
160	The bivariate distribution of amyloid-Î² and tau: relationship with established neurocognitive clinical syndromes. Brain, 2019, 142, 3230-3242.	7.6	129
161	Cognitive function after surgery with regional or general anesthesia: A populationâ€based study. Alzheimer's and Dementia, 2019, 15, 1243-1252.	0.8	13
162	Cardiometabolic Health and Longitudinal Progression of White Matter Hyperintensity. Stroke, 2019, 50, 3037-3044.	2.0	39

#	Article	IF	Citations
163	Elevated Plasma Ceramides Are Associated With Higher White Matter Hyperintensity Volumeâ€"Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 2431-2436.	2.4	8
164	Antemortem volume loss mirrors TDP-43 staging in older adults with non-frontotemporal lobar degeneration. Brain, 2019, 142, 3621-3635.	7.6	37
165	Factors Associated With Meningioma Detected in a Population-Based Sample. Mayo Clinic Proceedings, 2019, 94, 254-261.	3.0	7
166	The influence of tau, amyloid, alpha-synuclein, TDP-43, and vascular pathology in clinically normal elderly individuals. Neurobiology of Aging, 2019, 77, 26-36.	3.1	51
167	A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimerâ€™s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. Acta Neuropathologica, 2019, 138, 237-250.	7.7	87
168	Progressive agrammatic aphasia without apraxia of speech as a distinct syndrome. Brain, 2019, 142, 2466-2482.	7.6	33
169	Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia. JAMA - Journal of the American Medical Association, 2019, 321, 2316.	7.4	223
170	Neuropsychological subtypes of incident mild cognitive impairment in the Mayo Clinic Study of Aging. Alzheimer's and Dementia, 2019, 15, 878-887.	0.8	41
171	Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease. Alzheimer's and Dementia, 2019, 15, 927-939.	0.8	48
172	Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults. Neurology, 2019, 93, e29-e39.	1.1	62
173	Plasma and CSF neurofilament light. Neurology, 2019, 93, e252-e260.	1.1	160
174	White matter hyperintensities: relationship to amyloid and tau burden. Brain, 2019, 142, 2483-2491.	7.6	126
175	Longitudinal tau-PET uptake and atrophy in atypical Alzheimer's disease. NeuroImage: Clinical, 2019, 23, 101823.	2.7	54
176	A brief history of â€œAlzheimer diseaseâ€. Neurology, 2019, 92, 1053-1059.	1.1	52
177	Brain atrophy in primary ageâ€related tauopathy is linked to transactive response DNAâ€binding protein of 43 kDa. Alzheimer's and Dementia, 2019, 15, 799-806.	0.8	14
178	Association of MAPT Subhaplotypes With Risk of Progressive Supranuclear Palsy and Severity of Tau Pathology. JAMA Neurology, 2019, 76, 710.	9.0	39
179	The metabolic brain signature of cognitive resilience in the 80+: beyond Alzheimer pathologies. Brain, 2019, 142, 1134-1147.	7.6	72
180	CSF1R mutation presenting as dementia with Lewy bodies. Neurocase, 2019, 25, 17-20.	0.6	9

#	Article	IF	Citations
181	Cortical Î²-amyloid burden, neuropsychiatric symptoms, and cognitive status: the Mayo Clinic Study of Aging. Translational Psychiatry, 2019, 9, 123.	4.8	54
182	Amyloid PET and Changes in Clinical Management for Patients With Cognitive Impairment. JAMA - Journal of the American Medical Association, 2019, 321, 1258.	7.4	8
183	Longitudinal association between phosphatidylcholines, neuroimaging measures of Alzheimer's disease pathophysiology, and cognition in the Mayo Clinic Study of Aging. Neurobiology of Aging, 2019, 79, 43-49.	3.1	7
184	Heritability and genetic variance of dementia with Lewy bodies. Neurobiology of Disease, 2019, 127, 492-501.	4.4	29
185	Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy. Movement Disorders, 2019, 34, 1144-1153.	3.9	98
186	Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. Acta Neuropathologica, 2019, 137, 879-899.	7.7	90
187	Selective loss of cortical endothelial tight junction proteins during Alzheimerâ€™s disease progression. Brain, 2019, 142, 1077-1092.	7.6	120
188	Genetic meta-analysis of diagnosed Alzheimerâ€™s disease identifies new risk loci and implicates AÎ², tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	21.4	1,962
189	Entorhinal cortex tau, amyloid-Î², cortical thickness and memory performance in non-demented subjects. Brain, 2019, 142, 1148-1160.	7.6	68
190	ICâ€Pâ€086: CORTICAL ATROPHY PATTERNS OF EMPIRICALLY DERIVED INCIDENT MCI SUBTYPES IN THE MAYO CLINIC STUDY OF AGING. Alzheimer's and Dementia, 2019, 15, P76.	0.8	0
191	Functional Activity and Neuropsychiatric Symptoms in Normal Aging and Mild Cognitive Impairment. Alzheimer Disease and Associated Disorders, 2019, 33, 68-71.	1.3	8
192	Deep Learning Prediction of Mild Cognitive Impairment using Electronic Health Records. , 2019, 2019, 799-806.		17
193	Quantity and quality of mental activities and the risk of incident mild cognitive impairment. Neurology, 2019, 93, e548-e558.	1.1	38
194	Cerebrospinal fluid dynamics disorders. Neurology, 2019, 93, e2237-e2246.	1.1	19
195	ICâ€Pâ€022: BRAIN STATES AND TAU PET PATTERNS INTERACT ACROSS THE AGINGâ€ALZHEIMER'S CONTINUUM. Alzheimer's and Dementia, 2019, 15, P30.	0.8	0
196	Association Between Critical Care Admissions and Cognitive Trajectories in Older Adults*. Critical Care Medicine, 2019, 47, 1116-1124.	0.9	20
197	Association of Longitudinal Î²-Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia. JAMA Network Open, 2019, 2, e1916439.	5.9	22
198	Pathological, imaging and genetic characteristics support the existence of distinct TDP-43 types in non-FTLD brains. Acta Neuropathologica, 2019, 137, 227-238.	7.7	65

#	Article	IF	Citations
199	Cerebral microbleeds. Neurology, 2019, 92, e253-e262.	1.1	53
200	Association of Cerebrospinal Fluid Neurofilament Light Protein With Risk of Mild Cognitive Impairment Among Individuals Without Cognitive Impairment. JAMA Neurology, 2019, 76, 187.	9.0	66
201	MRI Outperforms [18F]AVâ€1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy. Movement Disorders, 2019, 34, 105-113.	3.9	33
202	¹⁸Fâ€AVâ€1451 uptake differs between dementia with lewy bodies and posterior cortical atrophy. Movement Disorders, 2019, 34, 344-352.	3.9	26
203	The influence of Î²-amyloid on [¹⁸ F]AV-1451 in semantic variant of primary progressive aphasia. Neurology, 2019, 92, e710-e722.	1.1	10
204	Multisite study of the relationships between antemortem [¹¹C]PIBâ€PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology. Alzheimer's and Dementia, 2019, 15, 205-216.	0.8	155
205	Automated and manual hippocampal segmentation techniques: Comparison of results, reproducibility and clinical applicability. NeuroImage: Clinical, 2019, 21, 101574.	2.7	11
206	A comprehensive screening of copy number variability in dementia with Lewy bodies. Neurobiology of Aging, 2019, 75, 223.e1-223.e10.	3.1	13
207	Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia, 2019, 15, 106-152.	0.8	302
208	Distinct cytokine profiles in human brains resilient to Alzheimer's pathology. Neurobiology of Disease, 2019, 121, 327-337.	4.4	79
209	Association of Bilateral Salpingo-Oophorectomy Before Menopause Onset With Medial Temporal Lobe Neurodegeneration. JAMA Neurology, 2019, 76, 95.	9.0	69
210	Predicting Progression to Mild Cognitive Impairment. Annals of Neurology, 2019, 85, 155-160.	5.3	32
211	Comparison of PC and iPad administrations of the Cogstate Brief Battery in the Mayo Clinic Study of Aging: Assessing cross-modality equivalence of computerized neuropsychological tests. Clinical Neuropsychologist, 2019, 33, 1102-1126.	2.3	13
212	A Comparison of Partial Volume Correction Techniques for Measuring Change in Serial Amyloid PET SUVR. Journal of Alzheimer's Disease, 2019, 67, 181-195.	2.6	48
213	Automated detection of imaging features of disproportionately enlarged subarachnoid space hydrocephalus using machine learning methods. NeuroImage: Clinical, 2019, 21, 101605.	2.7	29
214	The Cross-sectional and Longitudinal Associations Between IL-6, IL-10, and TNFÎ± and Cognitive Outcomes in the Mayo Clinic Study of Aging. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2019, 74, 1289-1295.	3.6	42
215	Relationship Between Risk Factors and Brain Reserve in Late Middle Age: Implications for Cognitive Aging. Frontiers in Aging Neuroscience, 2019, 11, 355.	3.4	25
216	The association between peripheral total IGF-1, IGFBP-3, and IGF-1/IGFBP-3 and functional and cognitive outcomes in the Mayo Clinic Study of Aging. Neurobiology of Aging, 2018, 66, 68-74.	3.1	30

#	Article	IF	Citations
217	Joint associations of Î²-amyloidosis and cortical thickness with cognition. Neurobiology of Aging, 2018, 65, 121-131.	3.1	27
218	White Matter Reference Region in PET Studies of ¹¹C-Pittsburgh Compound B Uptake: Effects of Age and Amyloid-Î² Deposition. Journal of Nuclear Medicine, 2018, 59, 1583-1589.	5.0	37
219	Frequency of Acute and Subacute Infarcts in a Population-Based Study. Mayo Clinic Proceedings, 2018, 93, 300-306.	3.0	5
220	Plasma phosphoâ€tau181 increases with Alzheimer's disease clinical severity and is associated with tauâ€• and amyloidâ€positron emission tomography. Alzheimer's and Dementia, 2018, 14, 989-997.	0.8	386
221	Leisure-Time Physical Activity and the Risk of Incident Dementia: The Mayo Clinic Study of Aging. Journal of Alzheimer's Disease, 2018, 63, 149-155.	2.6	33
222	The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable. Alzheimer's and Dementia, 2018, 14, 563-575.	0.8	98
223	Elevated medial temporal lobe and pervasive brain tauâ€PET signal in normal participants. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 210-216.	2.4	19
224	[¹⁸F]AVâ€1451 tauâ€PET and primary progressive aphasia. Annals of Neurology, 2018, 83, 599-611.	5.3	73
225	Tau-PET imaging with [18F]AV-1451 in primary progressive apraxia of speech. Cortex, 2018, 99, 358-374.	2.4	42
226	Tau-negative amnestic dementia masquerading as Alzheimer disease dementia. Neurology, 2018, 90, e940-e946.	1.1	24
227	In vivo ¹⁸ F-AV-1451 tau PET signal in MAPT mutation carriers varies by expected tau isoforms. Neurology, 2018, 90, e947-e954.	1.1	60
228	Sex differences in cerebrovascular pathologies on FLAIR in cognitively unimpaired elderly. Neurology, 2018, 90, e466-e473.	1.1	55
229	Potentially Modifiable Risk Factors for Long-Term Cognitive Impairment After Critical Illness: A Systematic Review. Mayo Clinic Proceedings, 2018, 93, 68-82.	3.0	69
230	Practice guideline update summary: Mild cognitive impairment. Neurology, 2018, 90, 126-135.	1.1	1,263
231	Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer's disease in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2018, 48, 3-9.	2.2	27
232	[¹⁸F]AVâ€1451 clustering of entorhinal and cortical uptake in Alzheimer's disease. Annals of Neurology, 2018, 83, 248-257.	5.3	67
233	Widespread brain tau and its association with ageing, Braak stage and Alzheimerâ€™s dementia. Brain, 2018, 141, 271-287.	7.6	218
234	Longitudinal Association Between Brain Amyloid-Beta and Gait in the Mayo Clinic Study of Aging. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2018, 73, 1244-1250.	3.6	30

#	Article	IF	Citations
235	Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting. JAMA Neurology, 2018, 75, 970.	9.0	116
236	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurology, The, 2018, 17, 548-558.	10.2	97
237	Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 1005-1014.	0.8	80
238	Longitudinal tau PET in ageing and Alzheimerâ€™s disease. Brain, 2018, 141, 1517-1528.	7.6	309
239	Disrupted functional connectivity in primary progressive apraxia of speech. NeuroImage: Clinical, 2018, 18, 617-629.	2.7	36
240	Trajectories of plasma IGF-1, IGFBP-3, and their ratio in the Mayo Clinic Study of Aging. Experimental Gerontology, 2018, 106, 67-73.	2.8	13
241	Association of Excessive Daytime Sleepiness With Longitudinal Î²-Amyloid Accumulation in Elderly Persons Without Dementia. JAMA Neurology, 2018, 75, 672.	9.0	150
242	FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis. Brain, 2018, 141, 1201-1217.	7.6	67
243	Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 739-749.	3.0	34
244	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet Neurology, The, 2018, 17, 64-74.	10.2	195
245	Association Between Microinfarcts and Blood Pressure Trajectories. JAMA Neurology, 2018, 75, 212.	9.0	15
246	Depressive and anxiety symptoms and cortical amyloid deposition among cognitively normal elderly persons: the Mayo Clinic Study of Aging. International Psychogeriatrics, 2018, 30, 245-251.	1.0	52
247	Conserved brain myelination networks are altered in Alzheimer's and other neurodegenerative diseases. Alzheimer's and Dementia, 2018, 14, 352-366.	0.8	116
248	Pittsburgh compound B (PiB) PET imaging of meningioma and other intracranial tumors. Journal of Neuro-Oncology, 2018, 136, 373-378.	2.9	9
249	Plasma Sphingolipids are Associated With Gait Parameters in the Mayo Clinic Study of Aging. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2018, 73, 960-965.	3.6	19
250	P2â€491: SUBTLE COGNITIVE DYSFUNCTION ON COGSTATE IS ASSOCIATED WITH BIOMARKER POSITIVE STATUS. Alzheimer's and Dementia, 2018, 14, P917.	0.8	0
251	P3â€221: LONGITUDINAL ASSOCIATION BETWEEN PHOSPHATIDYLCHOLINES, NEUROIMAGING MEASURES OF ALZHEIMER'S DISEASE PATHOPHYSIOLOGY, AND COGNITION IN THE MAYO CLINIC STUDY ON AGING. Alzheimer's and Dementia, 2018, 14, P1156.	0.8	0
252	P3â€238: LONGITUDINAL ASSOCIATIONS OF PLASMA NEUROFILAMENT LEVELS WITH AMYLOIDâ€PET, FDGâ€PET, AND COGNITION AMONG NONâ€DEMENTED PARTICIPANTS IN THE MAYO CLINIC STUDY ON AGING. Alzheimer's and Dementia, 2018, 14, P1163.	0.8	0

#	Article	IF	Citations
253	P1â€532: MEASURING LATENT COGNITIVE PROCESSES TO DETECT THE EARLIEST CHANGES IN AD. Alzheimer's and Dementia, 2018, 14, P536.	0.8	0
254	P2â€273: CEREBROSPINAL FLUID NEUROFILAMENT LIGHT PROTEIN AND RISK OF MILD COGNITIVE IMPAIRMENT IN THE MAYO CLINIC STUDY OF AGING. Alzheimer's and Dementia, 2018, 14, P782.	0.8	0
255	P4â€078: CONCORDEâ€AD: AN INTERNATIONAL NETWORK OF COHORTS FOR BETTER UNDERSTANDING OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1465.	0.8	0
256	ICâ€Pâ€144: PRINCIPAL AXES OF PHENOTYPIC VARIABILITY IN ALZHEIMER'S DISEASE DERIVED FROM AN FDGâ€PET BASED, UNSUPERVISED MACHINE LEARNING ALGORITHM. Alzheimer's and Dementia, 2018, 14, P122.	0.8	0
257	F2â€02â€01: NEUROFILAMENT LIGHT CHAIN IN AD IN CSF AND BLOOD. Alzheimer's and Dementia, 2018, 14, P603.	0.8	0
258	P1â€160: ABI3 AND PLCG2 AS RISK FACTORS FOR ALZHEIMER'S DISEASE IN CAUCASIANS AND AFRICAN AMERICANS. Alzheimer's and Dementia, 2018, 14, P339.	0.8	0
259	O2â€13â€01: INCIDENCE OF CEREBRAL MICROBLEEDS AND AMYLOID BURDEN: THE MAYO CLINIC STUDY OF AGING. Alzheimer's and Dementia, 2018, 14, P652.	0.8	0
260	P1â€139: THE CONTRIBUTION OF SEXâ€SPECIFIC ASSOCIATIONS IN GENETIC STUDIES OF ALZHEIMER'S DISEASE PATHOLOGY. Alzheimer's and Dementia, 2018, 14, P327.	0.8	0
261	ICâ€Pâ€083: DIAGNOSTIC UTILITY OF [18F]AVâ€1451 PET, FDGâ€PET AND MRI TO DIFFERENTIATE THE THREE VARIANTS OF PRIMARY PROGRESSIVE APHASIA. Alzheimer's and Dementia, 2018, 14, P71.	0.8	0
262	ICâ€Pâ€019: LONGITUDINAL ACCUMULATION OF Î²â€AMYLOID ON PET IN DEMENTIA WITH LEWY BODIES AND RELATIONSHIP TO CLINICAL DISEASE PROGRESSION. Alzheimer's and Dementia, 2018, 14, P25.	0.8	0
263	Amyloid- and tau-PET imaging in a familial prion kindred. Neurology: Genetics, 2018, 4, e290.	1.9	4
264	P1â€414: STATINS AND BRAIN HEALTH: MEDICATION EFFECTS ON NEUROIMAGING BIOMARKERS IN OLDER INDIVIDUALS. Alzheimer's and Dementia, 2018, 14, P463.	0.8	0
265	FTS3â€01â€03: U.S. PERSPECTIVE ON CLINICAL AMYLOID IMAGING. Alzheimer's and Dementia, 2018, 14, P1004.	0.8	0
266	P1â€387: PRINCIPAL AXES OF PHENOTYPIC VARIABILITY IN ALZHEIMER'S DISEASE DERIVED FROM AN FDGâ€PET BASED UNSUPERVISED MACHINE LEARNING ALGORITHM. Alzheimer's and Dementia, 2018, 14, P449.	0.8	0
267	P3â€597: MEDIAL TEMPORAL LOBE NEURODEGENERATION OBSERVED IN WOMEN WHO UNDERWENT BILATERAL OOPHORECTOMY BEFORE THE ONSET OF MENOPAUSE. Alzheimer's and Dementia, 2018, 14, P1356.	0.8	0
268	P3â€424: LONGITUDINAL ACCUMULATION OF Î²â€AMYLOID ON PET IN DEMENTIA WITH LEWY BODIES AND RELATIONSHIP TO CLINICAL DISEASE PROGRESSION. Alzheimer's and Dementia, 2018, 14, P1271.	0.8	0
269	P3â€202: TDPâ€43 IN ATYPICAL ALZHEIMER'S DISEASE DEMENTIA. Alzheimer's and Dementia, 2018, 14, P1145.	0.8	0
270	Effect of Cognitive Status on the Receipt of Procedures Requiring Anesthesia and Critical Care Admissions in Older Adults. Mayo Clinic Proceedings, 2018, 93, 1552-1562.	3.0	7

#	Article	IF	Citations
271	Risk Factors for Persistent Cognitive Impairment After Critical Illness, Nested Case-Control Study. Critical Care Medicine, 2018, 46, 1977-1984.	0.9	28
272	Association Between Functional Performance and Alzheimer's Disease Biomarkers in Individuals Without Dementia. Journal of the American Geriatrics Society, 2018, 66, 2274-2281.	2.6	10
273	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. Brain, 2018, 141, 2895-2907.	7.6	39
274	Development of a cerebrovascular magnetic resonance imaging biomarker for cognitive aging. Annals of Neurology, 2018, 84, 705-716.	5.3	49
275	Association of Apolipoprotein E Îµ4 With Transactive Response DNA-Binding Protein 43. JAMA Neurology, 2018, 75, 1347.	9.0	60
276	P2â€407: COGNITIVE RESILIENCE IN 80+: PREDICTORS AND IMAGING CORRELATES OF COGNITION. Alzheimer's and Dementia, 2018, 14, P863.	0.8	0
277	ABI3 and PLCG2 missense variants as risk factors for neurodegenerative diseases in Caucasians and African Americans. Molecular Neurodegeneration, 2018, 13, 53.	10.8	75
278	Statins and Brain Health: Alzheimerâ€™s Disease and Cerebrovascular Disease Biomarkers in Older Adults. Journal of Alzheimer's Disease, 2018, 65, 1345-1352.	2.6	23
279	Mediterranean Diet, Its Components, and Amyloid Imaging Biomarkers. Journal of Alzheimer's Disease, 2018, 64, 281-290.	2.6	22
280	Regional cortical perfusion on arterial spin labeling MRI in dementia with Lewy bodies: Associations with clinical severity, glucose metabolism and tau PET. NeuroImage: Clinical, 2018, 19, 939-947.	2.7	31
281	Sex-specific genetic predictors of Alzheimerâ€™s disease biomarkers. Acta Neuropathologica, 2018, 136, 857-872.	7.7	87
282	Subjective cognitive decline and risk of MCI. Neurology, 2018, 91, e300-e312.	1.1	176
283	Prosodic and phonetic subtypes of primary progressive apraxia of speech. Brain and Language, 2018, 184, 54-65.	1.6	106
284	Non-right handed primary progressive apraxia of speech. Journal of the Neurological Sciences, 2018, 390, 246-254.	0.6	4
285	Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials. Alzheimer's and Dementia, 2018, 14, 1077-1087.	0.8	83
286	Mild Cognitive Impairment in Geriatrics. Clinics in Geriatric Medicine, 2018, 34, 563-589.	2.6	108
287	APOE Îµ4 is associated with severity of Lewy body pathology independent of Alzheimer pathology. Neurology, 2018, 91, e1182-e1195.	1.1	122
288	How early can we diagnose Alzheimer disease (and is it sufficient)?. Neurology, 2018, 91, 395-402.	1.1	60

#	Article	IF	Citations
289	Association of antidiabetic medication use, cognitive decline, and risk of cognitive impairment in older people with type 2 diabetes: Results from the populationâ€based Mayo Clinic Study of Aging. International Journal of Geriatric Psychiatry, 2018, 33, 1114-1120.	2.7	25
290	Association of telomere length with general cognitive trajectories: a meta-analysis of four prospective cohort studies. Neurobiology of Aging, 2018, 69, 111-116.	3.1	32
291	Cellular senescence in brain aging and neurodegenerative diseases: evidence and perspectives. Journal of Clinical Investigation, 2018, 128, 1208-1216.	8.2	289
292	Duration and Pathologic Correlates of Lewy Body Disease. JAMA Neurology, 2017, 74, 310.	9.0	48
293	ABCA7 loss-of-function variants, expression, and neurologic disease risk. Neurology: Genetics, 2017, 3, e126.	1.9	26
294	A robust biomarker of largeâ€scale network failure in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 152-161.	2.4	29
295	Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART). Acta Neuropathologica, 2017, 133, 705-715.	7.7	125
296	Association Between Mentally Stimulating Activities in Late Life and the Outcome of Incident Mild Cognitive Impairment, With an Analysis of the APOE Îµ4 Genotype. JAMA Neurology, 2017, 74, 332.	9.0	71
297	Genome-wide association study identifies four novel loci associated with Alzheimerâ€™s endophenotypes and disease modifiers. Acta Neuropathologica, 2017, 133, 839-856.	7.7	199
298	Contributions of imprecision in <scp>PET</scp>â€<scp>MRI</scp> rigid registration to imprecision in amyloid <scp>PET</scp><scp>SUVR</scp> measurements. Human Brain Mapping, 2017, 38, 3323-3336.	3.6	26
299	Evaluation of Amyloid Protective Factors and Alzheimer Disease Neurodegeneration Protective Factors in Elderly Individuals. JAMA Neurology, 2017, 74, 718.	9.0	107
300	Population-Based Prevalence of Cerebral Cavernous Malformations in Older Adults. JAMA Neurology, 2017, 74, 801.	9.0	81
301	Age-specific and sex-specific prevalence of cerebral Î²-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50â€“95 years: a cross-sectional study. Lancet Neurology, The, 2017, 16, 435-444.	10.2	241
302	Diagnostic dilemmas in Alzheimer's disease: Room for shared decision making. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 301-304.	3.7	28
303	In-depth clinico-pathological examination of RNA foci in a large cohort of C9ORF72 expansion carriers. Acta Neuropathologica, 2017, 134, 255-269.	7.7	76
304	Phenoconversion from probable rapid eye movement sleep behavior disorder to mild cognitive impairment to dementia in a populationâ€based sample. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 127-130.	2.4	6
305	Neuroimaging biomarkers and impaired olfaction in cognitively normal individuals. Annals of Neurology, 2017, 81, 871-882.	5.3	51
306	White-matter integrity on DTI and the pathologic staging of Alzheimer's disease. Neurobiology of Aging, 2017, 56, 172-179.	3.1	158

#	Article	IF	Citations
307	Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons. JAMA - Journal of the American Medical Association, 2017, 317, 2305.	7.4	311
308	Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials. Alzheimer's and Dementia, 2017, 13, e1-e85.	0.8	213
309	Association between tau deposition and antecedent amyloid-Î² accumulation rates in normal and early symptomatic individuals. Brain, 2017, 140, 1499-1512.	7.6	93
310	Randomized controlled trials in mild cognitive impairment. Neurology, 2017, 88, 1751-1758.	1.1	35
311	Effects of traumatic brain injury and posttraumatic stress disorder on development of Alzheimer's disease in Vietnam Veterans using the Alzheimer's Disease Neuroimaging Initiative: Preliminary report. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 177-188.	3.7	64
312	Brain tau deposition linked to systemic causes of death in normal elderly. Neurobiology of Aging, 2017, 50, 163-166.	3.1	2
313	Tauâ€PET uptake: Regional variation in average SUVR and impact of amyloid deposition. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 21-30.	2.4	86
314	The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement. Alzheimer's and Dementia, 2017, 13, 561-571.	0.8	266
315	Genome-wide, high-content siRNA screening identifies the Alzheimerâ€™s genetic risk factor FERMT2 as a major modulator of APP metabolism. Acta Neuropathologica, 2017, 133, 955-966.	7.7	60
316	A candidate regulatory variant at the TREM gene cluster associates with decreased Alzheimer's disease risk and increased TREML1 and TREM2 brain gene expression. Alzheimer's and Dementia, 2017, 13, 663-673.	0.8	48
317	Prevalence and Natural History of Superficial Siderosis. Stroke, 2017, 48, 3210-3214.	2.0	40
318	Targeted neurogenesis pathway-based gene analysis identifies ADORA2A associated with hippocampal volume in mild cognitive impairment and Alzheimer's disease. Neurobiology of Aging, 2017, 60, 92-103.	3.1	70
319	Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum. Cortex, 2017, 97, 143-159.	2.4	162
320	Age, vascular health, and Alzheimer disease biomarkers in an elderly sample. Annals of Neurology, 2017, 82, 706-718.	5.3	136
321	Uptake of AV-1451 in meningiomas. Annals of Nuclear Medicine, 2017, 31, 736-743.	2.2	7
322	Weighting and standardization of frequencies to determine prevalence of AD imaging biomarkers. Neurology, 2017, 89, 2039-2048.	1.1	15
323	Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer's disease: a longitudinal retrospective study. Lancet Neurology, The, 2017, 16, 917-924.	10.2	159
324	Nursing Home Use Across The Spectrum of Cognitive Decline: Merging Mayo Clinic Study of Aging With CMS MDS Assessments. Journal of the American Geriatrics Society, 2017, 65, 2235-2243.	2.6	2

#	Article	IF	Citations
325	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	21.4	783
326	Neurocognition in individuals with incidentally-identified meningioma. Journal of Neuro-Oncology, 2017, 134, 125-132.	2.9	25
327	Decreased Glutamate Levels in Patients with Amnestic Mild Cognitive Impairment: An sLASER Proton MR Spectroscopy and PiBâ€PET Study. Journal of Neuroimaging, 2017, 27, 630-636.	2.0	29
328	TIA1 Mutations in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Promote Phase Separation and Alter Stress Granule Dynamics. Neuron, 2017, 95, 808-816.e9.	8.1	493
329	Cortical Thickness and Depressive Symptoms in Cognitively Normal Individuals: The Mayo Clinic Study ofÂAging. Journal of Alzheimer's Disease, 2017, 58, 1273-1281.	2.6	15
330	Association of Plasma Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on Aging. JAMA Neurology, 2017, 74, 1073.	9.0	149
331	Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimerâ€™s disease. BMC Medical Genomics, 2017, 10, 29.	1.5	28
332	Abnormal expression of homeobox genes and transthyretin in C9ORF72 expansion carriers. Neurology: Genetics, 2017, 3, e161.	1.9	12
333	AVâ€1451 tau and Î²â€amyloid positron emission tomography imaging in dementia with Lewy bodies. Annals of Neurology, 2017, 81, 58-67.	5.3	152
334	Practice effects and longitudinal cognitive change in clinically normal older adults differ by Alzheimer imaging biomarker status. Clinical Neuropsychologist, 2017, 31, 99-117.	2.3	47
335	[¹⁸F]AVâ€1451 tau positron emission tomography in progressive supranuclear palsy. Movement Disorders, 2017, 32, 124-133.	3.9	136
336	Excessive daytime sleepiness and fatigue may indicate accelerated brain aging in cognitively normal late middle-aged and older adults. Sleep Medicine, 2017, 32, 236-243.	1.6	79
337	Mediterranean diet, micronutrients and macronutrients, and MRI measures of cortical thickness. Alzheimer's and Dementia, 2017, 13, 168-177.	0.8	110
338	FTDPâ€17 with Pick bodyâ€like inclusions associated with a novel tau mutation, p.E372G. Brain Pathology, 2017, 27, 612-626.	4.1	11
339	An investigation of cerebrovascular lesions in dementia with Lewy bodies compared to Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 257-266.	0.8	41
340	Cortical Thickness and Anxiety Symptoms Among Cognitively Normal Elderly Persons: The Mayo Clinic Study of Aging. Journal of Neuropsychiatry and Clinical Neurosciences, 2017, 29, 60-66.	1.8	16
341	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. Neurobiology of Aging, 2017, 49, 214.e13-214.e15.	3.1	12
342	Optimizing PiB-PET SUVR change-over-time measurement by a large-scale analysis of longitudinal reliability, plausibility, separability, and correlation with MMSE. NeuroImage, 2017, 144, 113-127.	4.2	59

#	Article	IF	Citations
343	Defining imaging biomarker cut points for brain aging and Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 205-216.	0.8	581
344	Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 83-91.	3.7	94
345	Tracking the development of agrammatic aphasia: A tensor-based morphometry study. Cortex, 2017, 90, 138-148.	2.4	22
346	Cerebral Amyloid Deposition Is Associated with Gait Parameters in the Mayo Clinic Study of Aging. Journal of the American Geriatrics Society, 2017, 65, 792-799.	2.6	41
347	[P1â€“393]: PATTERN OF HYPOPERFUSION ON ASL OVERLAPS WITH HYPOMETABOLISM ON FDGâ€PET IN DEMENTIA WITH LEWY BODIES. Alzheimer's and Dementia, 2017, 13, P418.	0.8	0
348	[P2â€“415]: THE MAYO CLINIC ADULT LIFESPAN TEMPLATE: BETTER QUANTIFICATION ACROSS THE LIFESPAN. Alzheimer's and Dementia, 2017, 13, P792.	0.8	33
349	[ICâ€Pâ€204]: SUBJECTâ€LEVEL ASSESSMENT OF REGIONAL CORRELATIONS BETWEEN TAUâ€PET, AMYLOIDâ€PET, MRI AND FDGâ€PET ACROSS THE CLINICAL SPECTRUM OF ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P149.	0.8	0
350	[F4â€“03â€“04]: INTERVENTIONS FOR PREVENTING COGNITIVE DECLINE AND DEMENTIA: RECOMMENDATIONS FROM A NATIONAL ACADEMIES OF SCIENCES, ENGINEERING, AND MEDICINE STUDY. Alzheimer's and Dementia, 2017, 13, P1214.	0.8	0
351	Distinct spatiotemporal accumulation of N-truncated and full-length amyloid-Î²42 in Alzheimerâ€™s disease. Brain, 2017, 140, 3301-3316.	7.6	14
352	¹ H-MRS metabolites and rate of Î²-amyloid accumulation on serial PET in clinically normal adults. Neurology, 2017, 89, 1391-1399.	1.1	18
353	Creating three dimensional models of Alzheimerâ€™s disease. 3D Printing in Medicine, 2017, 3, 13.	3.1	7
354	Novel GRN mutation presenting as an aphasic dementia and evolving into corticobasal syndrome. Neurology: Genetics, 2017, 3, e201.	1.9	2
355	Decreased Expression of Sulfatase 2 in the Brains of Alzheimerâ€™s Disease Patients: Implications for Regulation of Neuronal Cell Signaling. Journal of Alzheimer's Disease Reports, 2017, 1, 115-124.	2.2	13
356	Comparison of [18 F]Flutemetamol and [11 C]Pittsburgh Compound-B in cognitively normal young, cognitively normal elderly, and Alzheimer's disease dementia individuals. NeuroImage: Clinical, 2017, 16, 295-302.	2.7	30
357	FDG-PET and Neuropsychiatric Symptoms among Cognitively Normal Elderly Persons: The Mayo Clinic Study of Aging. Journal of Alzheimer's Disease, 2016, 53, 1609-1616.	2.6	35
358	A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology, 2016, 87, 539-547.	1.1	1,216
359	MAPT haplotype diversity in multiple system atrophy. Parkinsonism and Related Disorders, 2016, 30, 40-45.	2.2	23
360	Human whole genome genotype and transcriptome data for Alzheimerâ€™s and other neurodegenerative diseases. Scientific Data, 2016, 3, 160089.	5.3	361

#	Article	IF	Citations
361	First PET Imaging Studies With ⁶³Zn-Zinc Citrate in Healthy Human Participants and Patients With Alzheimer Disease. Molecular Imaging, 2016, 15, 153601211667379.	1.4	22
362	Serum Adiponectin Levels, Neuroimaging, and Cognition in the Mayo Clinic Study of Aging. Journal of Alzheimer's Disease, 2016, 53, 573-581.	2.6	65
363	FTS3â€03â€01: The U.S. National Alzheimerâ€™s Plan: Five Years Later. Alzheimer's and Dementia, 2016, 12, P278	0.8	0
364	Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 862-871.	0.8	93
365	RAB39B gene mutations are not a common cause of Parkinson's disease or dementia with Lewy bodies. Neurobiology of Aging, 2016, 45, 107-108.	3.1	21
366	Impact of sex and APOE4 on cerebral amyloid angiopathy in Alzheimerâ€™s disease. Acta Neuropathologica, 2016, 132, 225-234.	7.7	73
367	Multimorbidity and neuroimaging biomarkers among cognitively normal persons. Neurology, 2016, 86, 2077-2084.	1.1	27
368	Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults. JAMA Neurology, 2016, 73, 721.	9.0	235
369	Network-driven plasma proteomics expose molecular changes in the Alzheimerâ€™s brain. Molecular Neurodegeneration, 2016, 11, 31.	10.8	34
370	Soluble sortilin is present in excess and positively correlates with progranulin in CSF of aging individuals. Experimental Gerontology, 2016, 84, 96-100.	2.8	14
371	TYROBP genetic variants in early-onset Alzheimer's disease. Neurobiology of Aging, 2016, 48, 222.e9-222.e15.	3.1	69
372	Spt4 selectively regulates the expression of C9orf72 sense and antisense mutant transcripts. Science, 2016, 353, 708-712.	12.6	116
373	TREM2 p.R47H substitution is not associated with dementia with Lewy bodies. Neurology: Genetics, 2016, 2, e85.	1.9	16
374	An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathologica Communications, 2016, 4, 58.	5.2	388
375	Prosaposin is a regulator of progranulin levels and oligomerization. Nature Communications, 2016, 7, 11992.	12.8	68
376	Comparison of Gait Parameters forÂPredicting Cognitive Decline: TheÂMayoÂClinic Study of Aging. Journal of Alzheimer's Disease, 2016, 55, 559-567.	2.6	79
377	LRRK2 variation and dementia with Lewy bodies. Parkinsonism and Related Disorders, 2016, 31, 98-103.	2.2	30
378	A large-scale comparison of cortical thickness and volume methods for measuring Alzheimer's disease severity. NeuroImage: Clinical, 2016, 11, 802-812.	2.7	249

#	Article	IF	Citations
379	Amyloid-Î² deposition and regional grey matter atrophy rates in dementia with Lewy bodies. Brain, 2016, 139, 2740-2750.	7.6	68
380	Age and neurodegeneration imaging biomarkers in persons with Alzheimer disease dementia. Neurology, 2016, 87, 691-698.	1.1	22
381	Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum. Neurobiology of Aging, 2016, 46, 32-42.	3.1	20
382	Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a populationâ€based elderly cohort. Alzheimer's and Dementia, 2016, 12, 1226-1234.	0.8	107
383	Integration of bioinformatics and imaging informatics for identifying rare PSEN1 variants in Alzheimerâ€™s disease. BMC Medical Genomics, 2016, 9, 30.	1.5	20
384	Hippocampal volumes predict risk of dementia with Lewy bodies in mild cognitive impairment. Neurology, 2016, 87, 2317-2323.	1.1	44
385	CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia. Nature Communications, 2016, 7, 11253.	12.8	174
386	Timing of Physical Activity, Apolipoprotein E Îµ4 Genotype, and Risk of Incident Mild Cognitive Impairment. Journal of the American Geriatrics Society, 2016, 64, 2479-2486.	2.6	23
387	MAPT haplotype H1G is associated with increased risk of dementia with Lewy bodies. Alzheimer's and Dementia, 2016, 12, 1297-1304.	0.8	32
388	Predicting Survival in Dementia With Lewy Bodies With Hippocampal Volumetry. Movement Disorders, 2016, 31, 989-994.	3.9	32
389	Association of Mild Cognitive Impairment WithÂExposure to General Anesthesia for Surgical and Nonsurgical Procedures. Mayo Clinic Proceedings, 2016, 91, 208-217.	3.0	55
390	Updated TDP-43 in Alzheimerâ€™s disease staging scheme. Acta Neuropathologica, 2016, 131, 571-585.	7.7	244
391	Suspected non-Alzheimer disease pathophysiology â€” concept and controversy. Nature Reviews Neurology, 2016, 12, 117-124.	10.1	230
392	Cascading network failure across the Alzheimerâ€™s disease spectrum. Brain, 2016, 139, 547-562.	7.6	401
393	Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study. Lancet Neurology, The, 2016, 15, 56-64.	10.2	104
394	Frailty and Mortality Outcomes in Cognitively Normal Older People: Sex Differences in a Populationâ€Based Study. Journal of the American Geriatrics Society, 2016, 64, 132-137.	2.6	48
395	Effect of intellectual enrichment on AD biomarker trajectories. Neurology, 2016, 86, 1128-1135.	1.1	71
396	Decline in Weight and Incident Mild Cognitive Impairment. JAMA Neurology, 2016, 73, 439.	9.0	89

#	Article	IF	Citations
397	Influence of amyloid and APOE on cognitive performance in a late middleâ€aged cohort. Alzheimer's and Dementia, 2016, 12, 281-291.	0.8	45
398	Longitudinal decline in mild-to-moderate Alzheimer's disease: Analyses of placebo data from clinical trials. , 2016, 12, 598-603.		26
399	Plasma sphingolipid changes with autopsyâ€confirmed Lewy body or Alzheimer's pathology. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 3, 43-50.	2.4	44
400	Association Between Olfactory Dysfunction and Amnestic Mild Cognitive Impairment and Alzheimer Disease Dementia. JAMA Neurology, 2016, 73, 93.	9.0	294
401	Atrial fibrillation, cognitive impairment, and neuroimaging. Alzheimer's and Dementia, 2016, 12, 391-398.	0.8	58
402	Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community. JAMA Neurology, 2016, 73, 85.	9.0	160
403	Age and education corrected older adult normative data for a short form version of the Financial Capacity Instrument.. Psychological Assessment, 2016, 28, 737-749.	1.5	35
404	Low neural exosomal levels of cellular survival factors in Alzheimer's disease. Annals of Clinical and Translational Neurology, 2015, 2, 769-773.	3.7	162
405	Characterizing White Matter Tract Degeneration in Syndromic Variants of Alzheimerâ€™s Disease: A Diffusion Tensor Imaging Study. Journal of Alzheimer's Disease, 2015, 49, 633-643.	2.6	27
406	Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. Journal of Alzheimer's Disease, 2015, 48, S63-S86.	2.6	317
407	Genetically-controlled Vesicle-Associated Membrane Protein 1 expression may contribute to Alzheimerâ€™s pathophysiology and susceptibility. Molecular Neurodegeneration, 2015, 10, 18.	10.8	13
408	Diabetes is Associated with Worse ExecutiveÂFunction in Both Eastern andÂWestern Populations: Shanghai Aging Study andÂMayo Clinic Study of Aging. Journal of Alzheimer's Disease, 2015, 47, 167-176.	2.6	23
409	Mortality in Mild Cognitive Impairment Varies by Subtype, Sex, and Lifestyle Factors: The Mayo Clinic Study of Aging. Journal of Alzheimer's Disease, 2015, 45, 1237-1245.	2.6	41
410	Association of Pancreatic Polypeptide with Mild Cognitive Impairment Varies by APOE Îµ4 Allele. Frontiers in Aging Neuroscience, 2015, 7, 172.	3.4	6
411	Rarity of the Alzheimer Diseaseâ€“ProtectiveAPPA673T Variant in the United States. JAMA Neurology, 2015, 72, 209.	9.0	41
412	Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease. Neurology, 2015, 85, 40-47.	1.1	355
413	Mitochondrial targeting sequence variants of the CHCHD2 gene are a risk for Lewy body disorders. Neurology, 2015, 85, 2016-2025.	1.1	51
414	F5-04-04: Scd in a population-based sample: Progression to MCI. , 2015, 11, P308-P309.		0

#	Article	IF	Citations
415	Microbleeds in Atypical Presentations of Alzheimer's Disease: A Comparison to Dementia of the Alzheimer's Type. Journal of Alzheimer's Disease, 2015, 45, 1109-1117.	2.6	19
416	Working memory and language network dysfunctions in logopenic aphasia: a task-free fMRI comparison with Alzheimer's dementia. Neurobiology of Aging, 2015, 36, 1245-1252.	3.1	83
417	2014 Update of the Alzheimer's Disease Neuroimaging Initiative: AÂreview of papers published since its inception. Alzheimer's and Dementia, 2015, 11, e1-120.	0.8	261
418	Clinicopathologic and¹¹C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimerâ€™s disease spectrum. Brain, 2015, 138, 1370-1381.	7.6	270
419	Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. Alzheimer's and Dementia, 2015, 11, 865-884.	0.8	181
420	The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans. Alzheimer's and Dementia, 2015, 11, 772-791.	0.8	79
421	Alzheimer's Disease Neuroimaging Initiative 2 Clinical Core: Progress and plans. Alzheimer's and Dementia, 2015, 11, 734-739.	0.8	80
422	Sample size calculations for clinical trials targeting tauopathies: a new potential disease target. Journal of Neurology, 2015, 262, 2064-2072.	3.6	10
423	Frequency and topography of cerebral microbleeds in dementia with Lewy bodies compared to Alzheimer's disease. Parkinsonism and Related Disorders, 2015, 21, 1101-1104.	2.2	27
424	Neuropsychiatric symptoms, APOE Îµ4, and the risk of incident dementia. Neurology, 2015, 84, 935-943.	1.1	101
425	Risk and protective factors for cognitive impairment in persons aged 85 years and older. Neurology, 2015, 84, 1854-1861.	1.1	61
426	Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. Brain, 2015, 138, 761-771.	7.6	222
427	The Human Alzheimer Disease Project. JAMA Neurology, 2015, 72, 626.	9.0	6
428	Age, Sex, andAPOEÎµ4 Effects on Memory, Brain Structure, and Î²-Amyloid Across the Adult Life Span. JAMA Neurology, 2015, 72, 511.	9.0	305
429	APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern. Alzheimer's and Dementia, 2015, 11, 1417-1429.	0.8	157
430	Predicting the risk of mild cognitive impairment in the Mayo Clinic Study of Aging. Neurology, 2015, 84, 1433-1442.	1.1	101
431	Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials. Alzheimer's and Dementia, 2015, 11, 1069-1079.	0.8	22
432	Performance of the CogState computerized battery in the Mayo ClinicÂStudy on Aging. Alzheimer's and Dementia, 2015, 11, 1367-1376.	0.8	85

#	Article	IF	Citations
433	White matter integrity in dementia with Lewy bodies: a voxel-based analysis of diffusion tensor imaging. Neurobiology of Aging, 2015, 36, 2010-2017.	3.1	35
434	Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. Brain, 2015, 138, 3747-3759.	7.6	170
435	Multimorbidity and Risk of Mild Cognitive Impairment. Journal of the American Geriatrics Society, 2015, 63, 1783-1790.	2.6	135
436	Role of Î²-Amyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment. JAMA Neurology, 2015, 72, 1475.	9.0	23
437	Novel clinical associations with specific C9ORF72 transcripts in patients with repeat expansions in C9ORF72. Acta Neuropathologica, 2015, 130, 863-876.	7.7	104
438	Spectrum of cognition short of dementia. Neurology, 2015, 85, 1712-1721.	1.1	67
439	Selfâ€rated and informantâ€rated everyday function in comparison to objective markers of Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 1080-1089.	0.8	85
440	Late-onset Alzheimer disease risk variants mark brain regulatory loci. Neurology: Genetics, 2015, 1, e15.	1.9	64
441	Cerebellar c9RAN proteins associate with clinical and neuropathological characteristics of C9ORF72 repeat expansion carriers. Acta Neuropathologica, 2015, 130, 559-573.	7.7	89
442	Role for the microtubule-associated protein tau variant p.A152T in risk of Î±-synucleinopathies. Neurology, 2015, 85, 1680-1686.	1.1	31
443	GWAS of longitudinal amyloid accumulation on¹⁸F-florbetapir PET in Alzheimerâ€™s disease implicates microglial activation geneIL1RAP. Brain, 2015, 138, 3076-3088.	7.6	117
444	Direct medical costs and source of cost differences across the spectrum of cognitive decline: A populationâ€based study. Alzheimer's and Dementia, 2015, 11, 917-932.	0.8	70
445	Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies. Neurobiology of Aging, 2015, 36, 452-461.	3.1	113
446	Late-onset Alzheimerâ€™s risk variants in memory decline, incident mild cognitive impairment, and Alzheimerâ€™s disease. Neurobiology of Aging, 2015, 36, 60-67.	3.1	90
447	Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A caseâ€control study. Alzheimer's and Dementia, 2015, 11, 600.	0.8	656
448	MRS in Mild Cognitive Impairment: Early Differentiation of Dementia with Lewy Bodies and Alzheimer's Disease. Journal of Neuroimaging, 2015, 25, 269-274.	2.0	24
449	At the interface of sensory and motor dysfunctions and Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 70-98.	0.8	420
450	Abnormal daytime sleepiness in dementia with Lewy bodies compared to Alzheimerâ€™s disease using the Multiple Sleep Latency Test. Alzheimer's Research and Therapy, 2014, 6, 76.	6.2	45

#	Article	IF	Citations
451	2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease. , 2014, 10, S430-S452.		64
452	Antemortem MRI findings associated with microinfarcts at autopsy. Neurology, 2014, 82, 1951-1958.	1.1	45
453	Association of hypometabolism and amyloid levels in aging, normal subjects. Neurology, 2014, 82, 1959-1967.	1.1	73
454	Early Alzheimer's Disease Neuropathology Detected by Proton MR Spectroscopy. Journal of Neuroscience, 2014, 34, 16247-16255.	3.6	117
455	White Matter Integrity Determined With Diffusion Tensor Imaging in Older Adults Without Dementia. JAMA Neurology, 2014, 71, 1547.	9.0	57
456	Association of MAPT haplotypes with Alzheimerâ€™s disease risk and MAPT brain gene expression levels. Alzheimer's Research and Therapy, 2014, 6, 39.	6.2	106
457	Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease. JAMA Neurology, 2014, 71, 1394.	9.0	166
458	Association of Lifetime Intellectual Enrichment With Cognitive Decline in the Older Population. JAMA Neurology, 2014, 71, 1017.	9.0	160
459	A Prospective Study of Chronic Obstructive Pulmonary Disease and the Risk for Mild Cognitive Impairment. JAMA Neurology, 2014, 71, 581.	9.0	109
460	Hypothyroidism and Risk of Mild Cognitive Impairment in Elderly Persons. JAMA Neurology, 2014, 71, 201.	9.0	48
461	Dementia with Lewy bodies. Neurology, 2014, 83, 801-809.	1.1	143
462	Regional proton magnetic resonance spectroscopy patterns in dementia with Lewy bodies. Neurobiology of Aging, 2014, 35, 1483-1490.	3.1	29
463	Association of diabetes with amnestic and nonamnestic mild cognitiveÂimpairment. Alzheimer's and Dementia, 2014, 10, 18-26.	0.8	141
464	A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 844-852.	0.8	1,863
465	Ataxin-2 as potential disease modifier in C9ORF72 expansion carriers. Neurobiology of Aging, 2014, 35, 2421.e13-2421.e17.	3.1	74
466	Independent comparison of CogState computerized testing and a standard cognitive battery with neuroimaging. Alzheimer's and Dementia, 2014, 10, 779-789.	0.8	26
467	Short and long telomeres increase risk of amnestic mild cognitive impairment. Mechanisms of Ageing and Development, 2014, 141-142, 64-69.	4.6	34
468	Progranulin protein levels are differently regulated in plasma and CSF. Neurology, 2014, 82, 1871-1878.	1.1	70

#	Article	IF	Citations
469	Mild Cognitive Impairment and Mild Dementia: A Clinical Perspective. Mayo Clinic Proceedings, 2014, 89, 1452-1459.	3.0	227
470	Age-specific population frequencies of cerebral Î²-amyloidosis and neurodegeneration among people with normal cognitive function aged 50â€“89 years: a cross-sectional study. Lancet Neurology, The, 2014, 13, 997-1005.	10.2	297
471	Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurology, The, 2014, 13, 686-699.	10.2	302
472	Association of plasma and cortical amyloid beta is modulated by APOE Îµ4 status. Alzheimer's and Dementia, 2014, 10, e9-e18.	0.8	43
473	18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons. Neurobiology of Aging, 2014, 35, 2096-2106.	3.1	108
474	Improved DTI registration allows voxel-based analysis that outperforms Tract-Based Spatial Statistics. NeuroImage, 2014, 94, 65-78.	4.2	155
475	Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer's disease in veterans, using the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia, 2014, 10, S226-35.	0.8	51
476	Evaluation of memory endophenotypes for association with CLU , CR1, and PICALM variants in black and white subjects. , 2014, 10, 205-213.		40
477	Association of Mediterranean Diet with Mild Cognitive Impairment and Alzheimer's Disease: A Systematic Review and Meta-Analysis. Journal of Alzheimer's Disease, 2014, 39, 271-282.	2.6	540
478	ApoE variant p.V236E is associated with markedly reduced risk of Alzheimerâ€™s disease. Molecular Neurodegeneration, 2014, 9, 11.	10.8	57
479	Do preclinical Alzheimer's disease criteria work?. Lancet Neurology, The, 2013, 12, 933-935.	10.2	7
480	CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimer's and Dementia, 2013, 9, 251-261.	0.8	344
481	Mild cognitive impairment due to Alzheimer disease in the community. Annals of Neurology, 2013, 74, 199-208.	5.3	215
482	Practice Effects and Longitudinal Cognitive Change in Normal Aging vs. Incident Mild Cognitive Impairment and Dementia in The Mayo Clinic Study of Aging. Clinical Neuropsychologist, 2013, 27, 1247-1264.	2.3	124
483	Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology, 2013, 81, 1732-1740.	1.1	182
484	AÎ² Imaging: feasible, pertinent, and vital to progress in Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 209-219.	6.4	55
485	Mild Cognitive Impairment. New England Journal of Medicine, 2011, 364, 2227-2234.	27.0	1,032
486	The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Agingâ€Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's and Dementia, 2011, 7, 270-279.	0.8	7,498

#	Article	IF	Citations
487	Alzheimer's disease: progress in prediction. Lancet Neurology, The, 2010, 9, 4-5.	10.2	56
488	IC-03-01: Early MCI as an imaging target: Data from the National Alzheimer's Coordinating Center. , 2010, 6, S58-S58.		2
489	Early Diagnosis of Alzheimers Disease: Is MCI Too Late?. Current Alzheimer Research, 2009, 6, 324-330.	1.4	199
490	Mild Cognitive Impairment. Archives of Neurology, 2009, 66, 1447-55.	4.5	1,160
491	Commentary on â€œA roadmap for the prevention of dementia II: Leon Thal Symposium 2008.â€•A national registry on aging. , 2009, 5, 105-107.		1
492	Challenges in clinical research on Alzheimer's disease: Leon Thal's legacy. Alzheimer's and Dementia, 2008, 4, S88-90.	0.8	1
493	The Mayo Clinic Study of Aging: Design and Sampling, Participation, Baseline Measures and Sample Characteristics. Neuroepidemiology, 2008, 30, 58-69.	2.3	623
494	Mild Cognitive Impairment:An Overview. CNS Spectrums, 2008, 13, 45-53.	1.2	548
495	The current status of mild cognitive impairmentâ€”what do we tell our patients?. Nature Clinical Practice Neurology, 2007, 3, 60-61.	2.5	14
496	FOR DEBATE: IS MILD COGNITIVE IMPAIRMENT A CLINICALLY USEFUL CONCEPT?. International Psychogeriatrics, 2006, 18, 393.	1.0	59
497	Mild Cognitive Impairment Should Be Considered for DSM-V. Journal of Geriatric Psychiatry and Neurology, 2006, 19, 147-154.	2.3	58
498	Neuropathologic Features of Amnestic Mild Cognitive Impairment. Archives of Neurology, 2006, 63, 665.	4.5	562
499	Conversion. Neurology, 2006, 67, S12-3.	1.1	15
500	Mild Cognitive Impairment: Where Are We?. Alzheimer Disease and Associated Disorders, 2005, 19, 166-169.	1.3	24
501	Mild Cognitive Impairment: Is it Alzheimer's disease or Not?. Journal of Alzheimer's Disease, 2005, 7, 241-245.	2.6	40
502	Mild Cognitive Impairment as a Clinical Entity and Treatment Target. Archives of Neurology, 2005, 62, 1160.	4.5	773
503	Mild cognitive impairment: Useful or not?. , 2005, 1, 5-10.		20
504	Commentary on â€œDiagnosis of Alzheimer's disease: Two decades of progressâ€• , 2005, 1, 122-123.		0

#	Article	IF	Citations
505	Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment. New England Journal of Medicine, 2005, 352, 2379-2388.	27.0	1,709
506	Mild cognitive impairment clinical trials. Nature Reviews Drug Discovery, 2003, 2, 646-653.	46.4	155
507	Current Concepts in Mild Cognitive Impairment. Archives of Neurology, 2001, 58, 1985.	4.5	4,117
508	Substantial linkage disequilibrium across the insulin-degrading enzyme locus but no association with late-onset Alzheimer's disease. Human Genetics, 2001, 109, 646-652.	3.8	93
509	AGING, MILD COGNITIVE IMPAIRMENT, AND ALZHEIMER'S DISEASE. Neurologic Clinics, 2000, 18, 789-805.	1.8	116
510	Î±-2 macroglobulin gene and Alzheimer disease. Nature Genetics, 1999, 22, 17-19.	21.4	91
511	Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer's disease. Annals of Neurology, 1998, 43, 303-310.	5.3	173
512	Free and cued selective reminding test: Moans norms. Journal of Clinical and Experimental Neuropsychology, 1997, 19, 676-691.	1.3	66
513	Aging, Memory, and Mild Cognitive Impairment. International Psychogeriatrics, 1997, 9, 65-69.	1.0	758
514	Neuropsychological tests' norms above age 55: COWAT, BNT, MAE token, WRAT-R reading, AMNART, STROOP, TMT, and JLO. Clinical Neuropsychologist, 1996, 10, 262-278.	2.3	477
515	Nimodipine in the Treatment of Probable AlzheimerÊ¼s Disease. Clinical Drug Investigation, 1996, 11, 185-195.	2.2	53
516	No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease. Movement Disorders, 1995, 10, 566-573.	3.9	84
517	Patterns and Predictors of Institutionalization in Communityâ€Based Dementia Patients. Journal of the American Geriatrics Society, 1994, 42, 181-185.	2.6	132
518	Mayo's older americans normative studies: WAIS-R norms for ages 56 to 97. Neuropsychology, Development and Cognition Section D: the Clinical Neuropsychologist, 1992, 6, 1-30.	1.2	374
519	Primary progressive aphasia. Aphasiology, 1992, 6, 1-15.	2.2	46
520	Mild Cognitive Impairment: Transition from Aging to Alzheimer's Disease. , 0, , 141-151.		16